Abstract
Angiotensin II, a major effector protein of the renin-angiotensin, system plays important roles in the regulation of arterial pressure and intravascular volume. In addition, operating at the systemic, tissue, and cellular levels it modifies vascular structure and inflammation, thereby participating in the pathogenesis of hypertension, atherosclerosis, and vascular stiffening. Here recent findings regarding angiotensin II biology and their potential relevance for vascular biology and disease are discussed
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Re RN. New insights into target organ involvement in hypertension. Med Clin North Am. 2009;93:559–67.
Re RN. The renin-angiotensin systems. Med Clin North Am. 1987;71:877–95.
Re RN. Tissue renin angiotensin systems. Med Clin North Am. 2004;88:19–38.
Re RN. The clinical implication of tissue renin angiotensin systems. Curr Opin Cardiol. 2001;16:317–27.
Wolf G. Novel aspects of the renin-angiotensin-aldosterone-system. Front Biosci. 2008;13:4993–5005.
Burchfiel CM, Tracy RE, Chyou PH, et al. Cardiovascular risk factors and hyalinization of renal arterioles at autopsy. The Honolulu Heart Program. Arterioscler Thromb Vasc Biol. 1997;17:760–8.
Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension. 1992;19:464–74.
Schiffrin EL. Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy. Scand Cardiovasc J Suppl. 1998;47:15–21.
Harrison DG, Marvar PJ, Titze JM. Vascular inflammatory cells in hypertension. Front Physiol. 2012;3:128. Epub 2012 May 7.
Harrison DG, Guzik TJ. Studies of the T-cell angiotensin receptor using cre-lox technology: an unan-T-cellpated result. Circ Res. 2012;110:1543–5.
Zhang JD, Patel MB, Song YS, Griffiths R, Burchette J, Ruiz P, Sparks MA, Yan M, Howell DN, Gomez JA, Spurney RF, Coffman TM, Crowley SD. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res. 2012;110:1604–17.
Strawn WB, Richmond RS, Ann Tallant E, et al. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol. 2004;126:120–6.
Strawn WB, Ferrario CM. Angiotensin II AT1 receptor blockade normalizes CD11b1 monocyte production in bone marrow of hypercholesterolemic monkeys. Atherosclerosis. 2008;196:624–32. Epub 2007 Aug 9.
Re RN. Cellular biology of the renin-angiotensin systems. Arch Intern Med. 1984;144:2037–41.
Ribichini F, Pugno F, Ferrero V, et al. Cellular immunostaining of angiotensinconverting enzyme in human coronary atherosclerotic plaques. J Am Coll Cardiol. 2006;47:1143–9. Epub 2006 Feb 23.
Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary disease. Circulation. 1996;94:2756–67.
Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749–56.
Campbell-Boswell M, Robertson Jr AL. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol. 1981;35:265–76.
Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens. 2005;18(9 Pt 2):134S–41.
Jones ES, Vinh A, McCarthy CA, et al. AT(2) receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292–316.
Tang H, Nishishita T, Fitzgerald T, et al. Inhibition of AT1 receptor internalization by concanavalin A blocks angiotensin II-induced ERK activation in vascular smooth muscle cells. Involvement of epidermal growth factor receptor proteolysis but not AT1 receptor internalization. J Biol Chem. 2000;275:13420–6.
AdbAlla S, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem. 2001;276:39721–6.
AbdAlla S, Lother H, el Massiery A, et al. Increased AT(1) receptor heterodimers in preeclampsia medicate enhanced angiotensin II responsiveness. Nat Med. 2001;7:1003–9.
Singh BM, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med. 2003;163:1296–304.
Hu C, Dandapat A, Sun L, et al. Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension. 2008;52:556–62. Epub 2008 Jul 21.
Chappel MC, Ferrario CM. ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1–7). Kidney Int. 2006;70:8–10.
Varagic J, Ahmad S, Brosnihan KB, Groban L, Chappell MC, Tallant EA, Gallagher PE, Ferrario CM. Decreased cardiac Ang-(1–7) is associated with salt-induced cardiac remodeling and dysfunction. Ther Adv Cardiovasc Dis. 2010;4:17–25.
Trask AJ, Ferrario CM. Angiotensin-(1–7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 2007;25:162–74.
Xue H, Zhou L, Yuan P, Wang Z, Ni J, Yao T, Wang J, Huang Y, Yu C, Lu L. Counteraction between angiotensin II and angiotensin-(1–7) via activating angiotensin type I and Mas receptor on rat renal mesangial cells. Regul Pept. 2012;177:12–20.
Patel VB, Bodiga S, Fan D, Das SK, Wang Z, Wang W, Basu R, Zhong J, Kassiri Z, Oudit GY. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1–7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension. 2012;59:1195–203.
Fraga-Silva RA, Ferreira AJ, Dos Santos RA. (1–7)/mas receptor pathway in hypertension. Curr Hypertens Rep. 2013;15:31–8.
Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, Kanaoka T, Haku S, Uneda K, Masuda SI, Azuma K, Shigenaga AI, Koide Y, Tsurumi-Ikeya Y, Matsuda M, Toya Y, Tokita Y, Yamashita A, Umemura S. The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap. Curr Pharm Des. 2013;19:3043–8.
Tsukuda K, Mogi M, Iwanami J, Min LJ, Jing F, Ohshima K, Horiuchi M. Influence of angiotensin II type 1 receptor-associated protein on prenatal development and adult hypertension after maternal dietary protein restriction during pregnancy. J Am Soc Hypertens. 2012;6:324–30.
Guo DF, Chenier I, Tardif V, Orlov SN, Inagami T. Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. Biochem Biophys Res Commun. 2003;310:1254–65.
Daniele T, Di Tullio G, Santoro M, Turacchio G, De Matteis MA. ARAP1 regulates EGF receptor trafficking and signalling. Traffic. 2008;9:2221–35.
Cook JL, Re RN, de Haro DL, Abadie JM, Peters M, Alam J. The trafficking protein GABARAP binds to and enhances plasma membrane expression and function of the angiotensin II type 1 receptor. Circ Res. 2008;102:1539–47.
Alam J, Deharo D, Redding KM, Re RN, Cook JL. C-terminal processing of GABARAP is not required for trafficking of the angiotensin II type 1A receptor. Regul Pept. 2010;159:78–86.
Vitko JR, Re RN, Alam J, Cook JL. Cell-penetrating peptides corresponding to the angiotensin II Type 1 receptor reduce receptor accumulation and cell surface expression and signaling. Am J Hypertens. 2012;25:24–8.
Re RN, Chen B, Alam J, Cook JL. Reduction of blood pressure by AT1 receptor decoy peptides. Ochsner J. 2013;13:33–6.
Cook JL, Mills SJ, Naquin RT, Alam J, Re RN. Cleavage of the angiotensin II type 1 receptor and nuclear accumulation of the cytoplasmic carboxy-terminal fragment. Am J Physiol Cell Physiol. 2007;292:C1313–22. Epub 2006 Nov 22.
Cook JL, Mills SJ, Naquin R, Alam J, Re RN. Nuclear accumulation of the AT1 receptor in a rat vascular smooth muscle cell line: effects upon signal transduction and cellular proliferation. J Mol Cell Cardiol. 2006;40:696–707. Epub 2006 Mar 6.
Re RN. Lysosomal action of intracrine angiotensin II. Focus on “Intracellular angiotensin II activates rat myometrium”. Am J Physiol Cell Physiol. 2011;301:C553–4.
Neri Serneri GG, Boddi M, Coppo M, Chechi T, Zarone N, Moira M, Poggesi L, Margheri M, Simonetti I. Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation. 1996;94:1886–93.
Frohlich ED, Susic D. Sodium and its multiorgan targets. Circulation. 2011;124:1882–5.
Re RN. Toward a theory of intracrine hormone action. Regul Pept. 2002;106:1–6.
Re RN. The intracrine hypothesis and intracellular peptide hormone action. Bioessays. 2003;25:401–9.
Re RN, Cook JL. The intracrine hypothesis: an update. Regul Pept. 2005;133:1–9.
Re RN. The implications of intracrine hormone action for physiology and medicine. Am J Physiol Heart Circ Physiol. 2003;284:H751–7.
Spatazza J, Di Lullo E, Joliot A, Dupont E, Moya KL, Prochiantz A. Homeoprotein signaling in development, health, and disease: a shaking of dogmas offers challenges and promises from bench to bed. Pharmacol Rev. 2013;65:90–104.
Dupont E, Prochiantz A, Joliot A. Penetratin story: an overview. Methods Mol Biol. 2011;683:21–9.
Singh VP, Le B, Bhat VB, et al. High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007;293:H939–48.
Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P. Myocardial cell death in human diabetes. Circ Res. 2000;87:1123–32.
Re RN, Cook JL. Noncanonical intracrine action. J Am Soc Hypertens. 2011;5:435–48.
Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol. 2012;302:R518–30.
Re RN, Vizard DL, Brown J, Bryan SE. Angiotensin II receptors in chromatin fragments generated by micrococcal nuclease. Biochem Biophys Res Commun. 1984;119:220–7.
Erdmann B, Fuxe K, Ganten D. Subcellular localization of angiotensin II immunoreactivity in the rat cerebellar cortex. Hypertension. 1996;28:818–24.
Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297–306.
Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, Griendling KK. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med. 2008;45:1340–51.
Takeuchi K, Yamamoto K, Ohishi M, Takeshita H, Hongyo K, Kawai T, Takeda M, Kamide K, Kurtz TW, Rakugi H. Telmisartan modulates mitochondrial function in vascular smooth muscle cells. Hypertens Res. 2013;36:433–9. doi:10.1038/hr.2012.199.
Robertson Jr AL, Khairallah PA. Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle. Science. 1971;172:1138–9.
Goodfriend TL, Fyhrquist F, Gutmann F, Knych E, Hollemans H, Allmann D, Kent K, Cooper T. Clinical and conceptual uses of angiotensin receptors. In: Genest J, Koiw E, editors. Hypertension '72. Berlin: Springer; 1972. p. 549–63.
Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol. 2010;32:296–304.
Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, O’Rourke B, Walston JD. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci U S A. 2011;108:14849–54.
Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI, Chappell MC. Angiotensin-(1–7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension. 2010;55:166–71.
Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res. 2001;89:1138–46.
Cook JL, Giardina JF, Zhang Z, Re RN. Intracellular angiotensin II increases the long isoform of PDGF mRNA in rat hepatoma cells. J Mol Cell Cardiol. 2002;34:1525–37.
Redding KM, Chen BL, Singh A, Re RN, Navar LG, Seth DM, Sigmund CD, Tang WW, Cook JL. Transgenic mice expressing an intracellular fluorescent fusion of angiotensin II demonstrate renal thrombotic microangiopathy and elevated blood pressure. Am J Physiol Heart Circ Physiol. 2010;298:H1807–18.
Cook JL, Re RN. Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model. Am J Physiol Regul Integr Comp Physiol. 2012;302:R482–93.
Re RN, Cook JL. The mitochondrial component of intracrine action. Am J Physiol Heart Circ Physiol. 2010;299:H577–83.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Re, R.N., Cook, J.L. (2014). Emerging Aspects of Angiotensin Biology and Their Potential Role in the Vasculature. In: Safar, M., O'Rourke, M., Frohlich, E. (eds) Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. Springer, London. https://doi.org/10.1007/978-1-4471-5198-2_13
Download citation
DOI: https://doi.org/10.1007/978-1-4471-5198-2_13
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-5197-5
Online ISBN: 978-1-4471-5198-2
eBook Packages: MedicineMedicine (R0)